San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Neurana Pharmaceuticals is raising $64,888,250.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Kathleen Scott played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neurana Pharmaceuticals

Neurana Pharmaceuticals is developing a novel, non-opioid, non-drowsy, non-impairing treatment for acute and painful muscle spasms. Neurana’s lead product, tolperisone, has a pharmacological profile that may offer unique benefits to patients suffering from muscle spasms. Tolperisone has successfully completed a Phase 2 study and Phase 3 initiation is expected in the second half of 2020. Visionary management and investors committed to reducing the pain and disability that can accompany acute muscle spasms.

To learn more about Neurana Pharmaceuticals, visit http://www.neuranapharma.com/

Contact:
Kathleen Scott, Chief Financial Officer
617-640-5043

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved